



Antibody Research in the Era of COVID-19

Guest Editor:

Prof. Dr. Carolina Ramírez-Santana

Centro de Estudio de
Enfermedades Autoinmunes
(CREA), Escuela de Medicina y
Ciencias de la Salud, Universidad
del Rosario, Bogotá 111221,
Colombia

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

Dear Colleagues,

Currently, COVID-19 is continuing to spread around the world, and the duration of antibodies and antibody levels remain poorly understood. We hope this Special Issue will improve our understanding of the immune response in humans after SARS-CoV-2 infection.

We are pleased to invite you to share your work and data on vaccines (both COVID-19 and others), with emphasis on immune response, antibody, and autoimmune phenomena.

In this Special Issue, original research articles, reviews, as well as significant case reports are welcome. Research areas may include (but are not limited to) the following:

- Immune response of COVID-19 vaccination
- Side effects of vaccination
- Antibody titers
- Autoimmune/inflammatory syndrome induced by adjuvants

We look forward to receiving your contributions.

Prof. Dr. Carolina Ramírez-Santana
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com